Author:
Willeman Théo,Grundig Nathan,Pochon Christine,Michels David,Charpentier Nicolas,Eysseric-Guérin Hélène,Fouilhé Sam-Lai Nathalie,Stanke-Labesque Françoise,Revol Bruno
Abstract
Abstract
Background
3-methylmethcathinone (3-MMC) has been available on the European drug market for several years, but an increase in its availability seems to have occurred around 2020, associated with reports of harm and death. We aimed to analyze the composition of the supposed 3-MMC samples purchased and its concordance with the assumed composition of the drug.
Methods
A prospective multicenter (n = 6) study was conducted between February 2021 and September 2021 in Auvergne-Rhone-Alpes, France. The inclusion criteria were: 3-MMC users over 18 years of age in contact with a community-based organization (CBO) called AIDES. Consumption was evaluated with an anonymized questionnaire and samples of 3-MMC powder were analyzed with a combination of qualitative (GC–MS) and quantitative methods (UPLC-MS/MS), to compare the assumed and real compositions of the products purchased.
Results
We studied 45 samples provided by 33 users. The study population was predominantly male (91%), with a median age of 40 years, most were university graduates and regular users of 3-MMC. Intravenous drug use was reported by 15.2% of the population. Most of the users bought their 3-MMC online via the Clear Web. Drug testing was requested by 86% of the users, highlighting the need for this type of harm reduction strategy. The purity of the 3-MMC powder samples tested ranged from 21 to 98%. Other NPS drugs, such as 4-CEC (4-chloroethcathinone), 4-MMC, and 2-fluorodeschloroketamine (2-FDCK), supplied as methoxphenidine (MXP), were also detected.
Conclusion
This prospective study shows that 3-MMC purity and dose vary considerably. It also describes the characteristics of 3-MMC users and their expectations of a drug-checking program. Our data suggest that drug-checking services may be useful in this population. Health associations and laboratories should work together to help increase access to such programs.
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Medicine (miscellaneous)
Reference30 articles.
1. European monitoring centre for drugs and drug addiction. European drug report 2022: trends and developments 2022. https://www.emcdda.europa.eu/publications/edr/trends-developments/2022_en. Accessed 25 Oct 2022.
2. Edmundson C, Heinsbroek E, Glass R, Hope V, Mohammed H, White M, et al. Sexualised drug use in the United Kingdom (UK): a review of the literature. Int J Drug Policy. 2018;55:131–48. https://doi.org/10.1016/j.drugpo.2018.02.002.
3. Sewell J, Cambiano V, Speakman A, Lampe FC, Phillips A, Stuart D, et al. Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: findings from the AURAH2 study. Int J Drug Policy. 2019;68:54–61. https://doi.org/10.1016/j.drugpo.2019.03.021.
4. Batisse A, Eiden C, Deheul S, Monzon E, Djezzar S, Peyrière H. Chemsex practice in France: an update in addictovigilance data. Fundam Clin Pharmacol. 2021;36:397–404. https://doi.org/10.1111/fcp.12725.
5. Drevin G, Rossi L-H, Férec S, Briet M, Abbara C. Chemsex/slamsex-related intoxications: a case report involving gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature. Forensic Sci Int. 2021;321:110743. https://doi.org/10.1016/j.forsciint.2021.110743.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献